Particular dysregulation of ‘don't eat me’ immune checkpoints in haemophagocytic lymphohistiocytosis

Documenti analoghi

• Assessment of intrathecal therapy in the treatment of familial haemophagocytic lymphohistiocytosis
  di: Katarina Zivkovic, et al.
  Pubblicazione: (2025)
• Goodbye etoposide? Taking the leap to ruxolitinib in haemophagocytic lymphohistiocytosis
  di: Samuel A. Merrill, et al.
  Pubblicazione: (2024)
• A pilot study tracking immune cell subsets and activation profiles in adults with haemophagocytic lymphohistiocytosis treated with anakinra
  di: Mark J. Bishton, et al.
  Pubblicazione: (2025)
• Clinical and radiological spectrum of central nervous system restricted haemophagocytic lymphohistiocytosis
  di: Maha Zakariya Mohammed, et al.
  Pubblicazione: (2025)
• Ruxolitinib‐based regimen in children with autoimmune disease or autoinflammatory disease‐related haemophagocytic lymphohistiocytosis
  di: Zishi Fang, et al.
  Pubblicazione: (2024)